(2013) Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial. Clinical Oncology, Volume 25 (Number 2). pp. 109-116. doi:10.1016/j.clon.2012.10.005

Research output not available from this repository, contact author.

Request Changes to record.

Abstract

The mortality from breast cancer has improved steadily over the past two decades, in part because of the increased use of more effective adjuvant therapies. Thousands of women are routinely treated with intensive chemotherapy, which can be unpleasant, is expensive and is occasionally hazardous. Oncologists have long known that some of these women may not need treatment, either because they have a low risk of relapse or because they have tumour biology that makes them less sensitive to chemotherapy and more suitable for early adjuvant endocrine therapy. There is an urgent need to improve patient selection so that chemotherapy is restricted to those patients who will benefit from it. Here we review the emerging technologies that are available for improving patient selection for chemotherapy. We describe the OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.

Item Type:	Journal Article
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School
Journal or Publication Title:	Clinical Oncology
Publisher:	Elsevier Science London
ISSN:	0936-6555
Official Date:	February 2013
Dates:	Date Event February 2013 Published
Volume:	Volume 25
Number:	Number 2
Page Range:	pp. 109-116
DOI:	10.1016/j.clon.2012.10.005
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item